Common Stock, par value $0.0001 per share
- Symbol
- ALLR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Allarity Therapeutics, Inc.
Other Events
Item 8.01 Other Matters. On September 30, 2026, Allarity Therapeutics, Inc. (the “Company”) provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities, which support the clinical development of stenoparib and expand potential external partnership opportunities.…
Company context
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.
Current securities
Registered securities in this filing
ALLARITY THERAPEUTICS, INC. · 8-K · Filed 2026-10-01
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Matters.
On September 30, 2026, Allarity Therapeutics, Inc. (the “Company”)
provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house
laboratory capabilities, which support the clinical development of stenoparib and expand potential external partnership opportunities.
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121) - a differentiated, dual PARP and WNT pathway inhibitor - today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparib’s clinical development while expanding external partnership opportunities. Allarity Therapeutics was established on its proprietary patient selection technology - the Drug Response Predictor (DRP®). DRP® allows Allarity to assess a patient’s tumor tissue for the gene expression changes that indicate the patient’s tumor is either more or less likely to respond to a given cancer therapy. DRP® tests have been successfully developed for dozens of can…
Open exhibit ↗